Methods
METASTATIC GASTRIC CANCER
The PARALLEL‐303 study (NCT03427814) investigated the efficacy and safety of pamiparib 60 mg orally (PO) twice daily (BID) versus placebo PO BID as maintenance therapy in patients with inoperable locally advanced or metastatic gastric cancer that responded to platinum‐based first‐line chemotherapy. The primary endpoint of this double‐blind, randomized, global phase 2 study was progression‐free survival (PFS) (RECIST version 1.1; per investigator assessment). Secondary endpoints included overall survival (OS) and safety.